Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patient adherence to treatment. Despite Viking's strong gain, major obesity drug peers like Eli Lilly and Novo Nordisk showed minimal stock movement, indicating this catalyst is seen as company-specific rather than sector-wide. Viking plans to start oral Phase 3 trials in Q4 2026 and aims to be the first with an oral dual GLP-1/GIP agonist on the market.
As of Sep 23, 2026 00:31 WIB, Eli Lilly (LLY) shares show a modest 0.44% gain trading at USD 1,169.57, while Novo Nordisk (NVO) is down 0.93% at USD 39.45 on Pluang. Despite Viking Therapeutics' notable 26.5% surge, these major obesity drug peers exhibit minimal movement, with Pluang order activity favoring selling for Eli Lilly at 66%. Novo Nordisk, however, sees strong buying interest at 87%. The most notable figure remains Viking's 26.5% jump, standing out against the steadier performance of its peers.
Ken Langone, co-founder of Home Depot, stated that Eli Lilly stock could reach $2,000 within the next 3 to 4 years, challenging the long-term success of his Home Depot investment. Eli Lilly has shown strong growth, up over 54% in the past year despit...
Eli Lilly reported a strong quarter beating revenue and earnings estimates, driven by its dominant GLP-1 obesity and diabetes drugs Mounjaro and Zepbound. Despite this, the stock fell 7.2% over the past month due to pricing pressures and competition....
Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for ...
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
